Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6023 Combination Therapy in Advanced Breast Cancer
NCT07597629Phase 2Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6023 in breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
SYS6023
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07597629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597629.